12:36 PM EDT, 10/08/2024 (MT Newswires) -- T2 Biosystems ( TTOO ) and Prxcision said Tuesday they will comarket diagnostic solutions to identify suspected bloodstream infections and sepsis, and tackle the growing issue of antibiotic resistance.

T2 Biosystems' ( TTOO ) fast blood tests, combined with Prxcision's AI platform, will provide quick identification of pathogens "in hours, not days," and insights to care providers.

The collaboration is expected to boost product adoption improve outcomes and reduce costs related to antimicrobial resistance and sepsis management, according to a joint statement.

T2 Biosystems ( TTOO ) shares were up 1% in recent trading.

Price: 1.65, Change: +0.02, Percent Change: +1.23